Steven K. Davidsen

Abbott Fund — United States

Medicine · Health Sciences

36h-index4.3kcitations120works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Peptidase Inhibition and Analysis(24), Protease and Inhibitor Mechanisms(18), HER2/EGFR in Cancer Research(14), Histone Deacetylase Inhibitors Research(13), Angiogenesis and VEGF in Cancer(12)

Publications120 total

Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families
Journal of Pharmacology and Experimental Therapeutics·2012· 22 cited
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families
Bioorganic & Medicinal Chemistry Letters·2012· 30 citedOpen Access
A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model
Cancer Chemotherapy and Pharmacology·2011· 30 cited
Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.
Molecular Cancer Therapeutics·2011· 1 cited
Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.
Molecular Cancer Therapeutics·2011· 1 cited
Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases
Bioorganic & Medicinal Chemistry Letters·2011· 49 cited
ABT-869, a Multitargeted Receptor Tyrosine Kinase Inhibitor, Reduces Tumor Microvascularity and Improves Vascular Wall Integrity in Preclinical Tumor Models
Journal of Pharmacology and Experimental Therapeutics·2011· 21 cited
Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases
Bioorganic & Medicinal Chemistry Letters·2010· 25 citedOpen Access
Imidazo[2,1-b]thiazoles: Multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases
Bioorganic & Medicinal Chemistry Letters·2010· 56 citedOpen Access
Abstract B14: The broad spectrum antitumor efficacy and tolerability of the RTK inhibitor, linifanib (ABT-869) alone and in combination with various cytotoxic therapies
Molecular Cancer Therapeutics·2009
Abstract A248: Substituted 4-amino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidines as multitargeted inhibitors targeting insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor tyrosine kinases
Molecular Cancer Therapeutics·2009
Abstract A245: Imidazo[2,1-b]thiazole and imidazo[1,2-a]pyridine amides as novel inhibitors of the insulin-like growth factor (IGF1R) and members of the epidermal growth factor family of tyrosine kinases
Molecular Cancer Therapeutics·2009
Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605
BMC Cancer·2009· 19 citedOpen Access
Abstract #1789: Cellular activity of ABT-869 against colony-stimulating-factor-1 receptor (CSF-1R) in macrophage-like cell lines
Cancer Research·2009
Elucidating Compound Selectivity: Integration of Chemoproteomic, Protein Signaling, and Gene Expression Profiles
The FASEB Journal·2009
Effect of the Multitargeted Receptor Tyrosine Kinase Inhibitor, ABT-869 [N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea], on Blood Pressure in Conscious Rats and Mice: Reversal with Antihypertensive Agents and Effect on Tumor Growth Inhibition
Journal of Pharmacology and Experimental Therapeutics·2009· 20 cited
ETA Receptor Blockade With Atrasentan Prevents Hypertension With the Multitargeted Tyrosine Kinase Inhibitor ABT-869 in Telemetry-instrumented Rats
Journal of Cardiovascular Pharmacology·2009· 41 cited
Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases
Bioorganic & Medicinal Chemistry Letters·2009· 19 citedOpen Access
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
Blood·2009· 160 citedOpen Access
Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.
Blood·2008· 2 cited
page 1 of 6Next →

Frequent Co-authors

Keith B. Glaser(25), Patrick A. Marcotte(24), Daniel H. Albert(24), Lori J. Pease(19), Michael L. Curtin(18), Jennifer J. Bouska(15), Michael R. Michaelides(13), Kent D. Stewart(11), Paul Tapang(11), Robin R. Frey(11), H. Robin Heyman(11), Jun Guo(10), Junling Li(10), Douglas W. Morgan(9), Yujia Dai(9), Michael R. Michaelides(9), George S. Sheppard(8), Douglas H. Steinman(7), Yan Guo(7), Robert B. Garland(7)